Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Responses to Bronchoscopic Instillation of PPD in the Lung
NCT05027958Phase 1Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- May 2022
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of tuberculin purified protein derivative (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) at Day 21. Started May 2022; status: completed.
02
Drugs
tuberculin purified protein derivative
Beyond the preview
Go deeper on NCT05027958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027958.